

Magle Group Announces Revised Publication Date for Q3 2025 Due to Ongoing Consolidation Processes

Malmö, Sweden – Magle Group announces a revised publication date for its Q3 2025 financial report. The Q3 2025 financial report, originally scheduled for release on 31 October 2025, will now be published on 14 November 2025.

The revised timeline is due to the consolidation and integration process following the acquisition of Magle Biopolymers. As the entity is integrated into Magle Group's financial structure, additional time is required to ensure the highest level of accuracy and transparency in reporting.

Magle Group maintains confidence in the long-term strategic benefits of the acquisition and the growth opportunities they create for the company's future development

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglechemos

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Magle Group Announces Revised Publication Date for Q3 2025 Due to Ongoing Consolidation Processes